Inhibitory effect of statins on inflammation-related pathways in human abdominal aortic aneurysm tissue

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 11213-11228

  Yoshimura, Koichi ^a,b   Nagasawa, Ayako ^a,c   Kudo, Junichi ^a   Onoda, Masahiko ^a   Morikage, Noriyasu ^a   Furutani, Akira ^a   Aoki, Hiroki ^d   Hamano, Kimikazu ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI PREFECTURAL UNIVERSITY   (Japan)

^c NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^d KURUME UNIVERSITY   (Japan)

Author keywords

Abdominal aortic aneurysm; Nuclear factor B; Statin

Indexed keywords

4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL] AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ANTHRA [1,9 CD] PYRAZOL 6 (2H) ONE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GELATINASE A; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; PITAVASTATIN; RAC1 PROTEIN; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; AMINOQUINOLINE DERIVATIVE; ANTHRACENE DERIVATIVE; CCL8 PROTEIN, HUMAN; PYRAZOLANTHRONE; PYRIMIDINE DERIVATIVE; TUMOR NECROSIS FACTOR;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ORGAN CULTURE; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; TISSUE HOMOGENATE; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY; ABDOMINAL AORTA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IN VITRO STUDY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTHRACENES; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CHEMOKINE CCL8; CHEMOKINE CXCL5; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IN VITRO TECHNIQUES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NF-KAPPA B; PYRIMIDINES; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84930679521     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160511213     Document Type: Article

References (59)

1. Sakalihasan, N.; Limet, R.; Defawe, O.D. Abdominal aortic aneurysm. Lancet 2005, 365, 1577–1589.
2. Moll, F.L.; Powell, J.T.; Fraedrich, G.; Verzini, F.; Haulon, S.; Waltham, M.; van Herwaarden, J.A.; Holt, P.J.E.; van Keulen, J.W.; Rantner, B.; et al. Management of abdominal aortic aneurysms clinical practice guidelines of the european society for vascular surgery. Eur. J. Vasc. Endovasc. Surg. 2011, 41, S1–S58.
3. Golledge, J.; Muller, J.; Daugherty, A.; Norman, P. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2605–2613.
4. Aoki, H.; Yoshimura, K.; Matsuzaki, M. Turning back the clock: Regression of abdominal aortic aneurysms via pharmacotherapy. J. Mol. Med. (Berl.) 2007, 85, 1077–1088.
5. Yoshimura, K.; Aoki, H. Recent advances in pharmacotherapy development for abdominal aortic aneurysm. Int. J. Vasc. Med. 2012, 2002, doi:10.1155/2012/648167.
6. Golledge, J. Targeting chemokines in aortic aneurysm: Could this be key to a novel therapy for a common problem? Arterioscler. Thromb. Vasc. Biol. 2013, 33, 670–672.
7. Yoshimura, K.; Aoki, H.; Ikeda, Y.; Fujii, K.; Akiyama, N.; Furutani, A.; Hoshii, Y.; Tanaka, N.; Ricci, R.; Ishihara, T.; et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat. Med. 2005, 11, 1330–1338.
8. Miyake, T.; Aoki, M.; Masaki, H.; Kawasaki, T.; Oishi, M.; Kataoka, K.; Ogihara, T.; Kaneda, Y.; Morishita, R. Regression of abdominal aortic aneurysms by simultaneous inhibition of nuclear factor κB and Ets in a rabbit model. Circ. Res. 2007, 101, 1175–1184.
9. Yoshimura, K.; Aoki, H.; Ikeda, Y.; Furutani, A.; Hamano, K.; Matsuzaki, M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann. N. Y. Acad. Sci. 2006, 1085, 74–81.
10. Golledge, J.; Powell, J.T. Medical management of abdominal aortic aneurysm. Eur. J. Vasc. Endovasc. Surg. 2007, 34, 267–273.
11. Golledge, J.; Norman, P.E. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis 2011, 217, 57–63.
12. Kurosawa, K.; Matsumura, J.S.; Yamanouchi, D. Current status of medical treatment for abdominal aortic aneurysm. Circ. J. 2013, 77, 2860–2866.
13. Jain, M.K.; Ridker, P.M. Anti-inflammatory effects of statins: Clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 2005, 4, 977–987.
14. Takemoto, M.; Liao, J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 2001, 21, 1712–1719.
15. Schonbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: Statins as antiinflammatory agents? Circulation 2004, 109, II18–II126.
16. Nomura, S.; Yoshimura, K.; Akiyama, N.; Mikamo, A.; Furutani, A.; Aoki, H.; Matsuzaki, M.; Hamano, K. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins. Eur. Surg. Res. 2005, 37, 370–378.
17. Nagashima, H.; Aoka, Y.; Sakomura, Y.; Sakuta, A.; Aomi, S.; Ishizuka, N.; Hagiwara, N.; Kawana, M.; Kasanuki, H. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J. Vasc. Surg. 2002, 36, 158–163.
18. Wilson, W.R.; Evans, J.; Bell, P.R.; Thompson, M.M. HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 2005, 30, 259–262.
19. Kudo, J.; Yoshimura, K.; Hamano, K. Simvastatin reduces secretion of monocyte chemoattractant proteins and matrix metalloproteinase-9 in human abdominal aortic aneurysms. Bull. Yamaguchi Med. Sch. 2007, 54, 47–56.
20. Kalyanasundaram, A.; Elmore, J.R.; Manazer, J.R.; Golden, A.; Franklin, D.P.; Galt, S.W.; Zakhary, E.M.; Carey, D.J. Simvastatin suppresses experimental aortic aneurysm expansion. J. Vasc. Surg. 2006, 43, 117–124.
21. Steinmetz, E.F.; Buckley, C.; Shames, M.L.; Ennis, T.L.; Vanvickle-Chavez, S.J.; Mao, D.; Goeddel, L.A.; Hawkins, C.J.; Thompson, R.W. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann. Surg. 2005, 241, 92–101.
22. Shiraya, S.; Miyake, T.; Aoki, M.; Yoshikazu, F.; Ohgi, S.; Nishimura, M.; Ogihara, T.; Morishita, R. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009, 202, 34–40.
23. Golledge, J.; Cullen, B.; Moran, C.; Rush, C. Efficacy of simvastatin in reducing aortic dilatation in mouse models of abdominal aortic aneurysm. Cardiovasc. Drugs Ther. 2010, 24, 373–378.
24. Karrowni, W.; Dughman, S.; Hajj, G.P.; Miller, F.J., Jr. Statin therapy reduces growth of abdominal aortic aneurysms. J. Investig. Med. 2011, 59, 1239–1243.
25. Schlosser, F.J.; Tangelder, M.J.; Verhagen, H.J.; van der Heijden, G.J.; Muhs, B.E.; van der Graaf, Y.; Moll, F.L. Growth predictors and prognosis of small abdominal aortic aneurysms. J. Vasc. Surg. 2008, 47, 1127–1133.
26. Schouten, O.; van Laanen, J.H.; Boersma, E.; Vidakovic, R.; Feringa, H.H.; Dunkelgrun, M.; Bax, J.J.; Koning, J.; van Urk, H.; Poldermans, D. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur. J. Vasc. Endovasc. Surg. 2006, 32, 21–26.
27. Sukhija, R.; Aronow, W.S.; Sandhu, R.; Kakar, P.; Babu, S. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am. J. Cardiol. 2006, 97, 279–280.
28. Sweeting, M.J.; Thompson, S.G.; Brown, L.C.; Greenhalgh, R.M.; Powell, J.T. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J. Vasc. Surg. 2010, 52, 1–4.
29. Thompson, A.; Cooper, J.A.; Fabricius, M.; Humphries, S.E.; Ashton, H.A.; Hafez, H. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J. Vasc. Surg. 2010, 52, 55–61.
30. Ferguson, C.D.; Clancy, P.; Bourke, B.; Walker, P.J.; Dear, A.; Buckenham, T.; Norman, P.; Golledge, J. Association of statin prescription with small abdominal aortic aneurysm progression. Am. Heart J. 2010, 159, 307–313.
31. Twine, C.P.; Williams, I.M. Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms. Br. J. Surg. 2011, 98, 346–353.
32. Wemmelund, H.; Hogh, A.; Hundborg, H.H.; Thomsen, R.W.; Johnsen, S.P.; Lindholt, J.S. Statin use and rupture of abdominal aortic aneurysm. Br. J. Surg. 2014, 101, 966–975.
33. Hamano, K.; Li, T.S.; Takahashi, M.; Kobayashi, T.; Shirasawa, B.; Ito, H.; Zempo, N. Enhanced tumor necrosis factor-α expression in small sized abdominal aortic aneurysms. World J. Surg. 2003, 27, 476–480.
34. Juvonen, J.; Surcel, H.M.; Satta, J.; Teppo, A.M.; Bloigu, A.; Syrjala, H.; Airaksinen, J.; Leinonen, M.; Saikku, P.; Juvonen, T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2843–2847.
35. Xiong, W.; MacTaggart, J.; Knispel, R.; Worth, J.; Persidsky, Y.; Baxter, B.T. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J. Immunol. 2009, 183, 2741–2746.
36. Pyo, R.; Lee, J.K.; Shipley, J.M.; Curci, J.A.; Mao, D.; Ziporin, S.J.; Ennis, T.L.; Shapiro, S.D.; Senior, R.M.; Thompson, R.W. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Investig. 2000, 105, 1641–1649.
37. Ortego, M.; Bustos, C.; Hernandez-Presa, M.A.; Tunon, J.; Diaz, C.; Hernandez, G.; Egido, J. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147, 253–261.
38. Middleton, R.K.; Lloyd, G.M.; Bown, M.J.; Cooper, N.J.; London, N.J.; Sayers, R.D. The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: A protein array study. J. Vasc. Surg. 2007, 45, 574–580.
39. Golledge, J.; Clancy, P.; Moran, C.; Biros, E.; Rush, C.; Walker, P.; Norman, P. The novel association of the chemokine CCL22 with abdominal aortic aneurysm. Am. J. Pathol. 2010, 176, 2098–2106.
40. Rush, C.; Nyara, M.; Moxon, J.V.; Trollope, A.; Cullen, B.; Golledge, J. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics 2009, 10, doi:10.1186/1471-2164-10-298.
41. Rashid, M.; Tawara, S.; Fukumoto, Y.; Seto, M.; Yano, K.; Shimokawa, H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ. J. 2009, 73, 361–370.
42. Chen, L.Y.; Ptasznik, A.; Pan, Z.K. RhoA and Rac1 signals in fMLP-induced NF-κB activation in human blood monocytes. Biochem. Biophys. Res. Commun. 2004, 319, 629–635.
43. Zampetaki, A.; Zhang, Z.; Hu, Y.; Xu, Q. Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-κB signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 2005, 288, H2946–H2954.
44. Yoshimura, K.; Aoki, H.; Ikeda, Y.; Furutani, A.; Hamano, K.; Matsuzaki, M. Identification of c-Jun N-terminal kinase as a therapeutic target for abdominal aortic aneurysm. Ann. N. Y. Acad. Sci. 2006, 1085, 403–406.
45. Bellosta, S.; Paoletti, R.; Corsini, A. Safety of statins: Focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109, III50–III57.
46. Bjorkhem-Bergman, L.; Lindh, J.D.; Bergman, P. What is a relevant statin concentration in cell experiments claiming pleiotropic effects? Br. J. Clin. Pharmacol. 2011, 72, 164–165.
47. Kajimoto, K.; Miyauchi, K.; Kasai, T.; Shimada, K.; Kojima, Y.; Shimada, A.; Niinami, H.; Amano, A.; Daida, H. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009, 206, 505–511.
48. Piechota-Polanczyk, A.; Goraca, A.; Demyanets, S.; Mittlboeck, M.; Domenig, C.; Neumayer, C.; Wojta, J.; Nanobachvili, J.; Huk, I.; Klinger, M. Simvastatin decreases free radicals formation in the human abdominal aortic aneurysm wall via NF-κB. Eur. J. Vasc. Endovasc. Surg. 2012, 44, 133–137.
49. Dawson, J.A.; Choke, E.; Loftus, I.M.; Cockerill, G.W.; Thompson, M.M. A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Eur. J. Vasc. Endovasc. Surg. 2011, 41, 28–35.
50. Hurks, R.; Hoefer, I.E.; Vink, A.; Pasterkamp, G.; Schoneveld, A.; Kerver, M.; de Vries, J.P.; Tangelder, M.J.; Moll, F.L. Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. Eur. J. Vasc. Endovasc. Surg. 2010, 39, 569–576.
51. Van der Meij, E.; Koning, G.G.; Vriens, P.W.; Peeters, M.F.; Meijer, C.A.; Kortekaas, K.E.; Dalman, R.L.; van Bockel, J.H.; Hanemaaijer, R.; Kooistra, T.; et al. A clinical evaluation of statin pleiotropy: Statins selectively and dose-dependently reduce vascular inflammation. PLoS ONE 2013, 8, e53882.
52. Takagi, H.; Matsui, M.; Umemoto, T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J. Vasc. Surg. 2010, 52, 1675–1681.
53. Coimbra, M.; Banciu, M.; Fens, M.H.; de Smet, L.; Cabaj, M.; Metselaar, J.M.; Storm, G.; Schiffelers, R.M. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J. Control. Release 2010, 148, 303–310.
54. Winter, P.M.; Caruthers, S.D.; Zhang, H.; Williams, T.A.; Wickline, S.A.; Lanza, G.M. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc. Imaging 2008, 1, 624–634.
55. Katsuki, S.; Matoba, T.; Nakashiro, S.; Sato, K.; Koga, J.; Nakano, K.; Nakano, Y.; Egusa, S.; Sunagawa, K.; Egashira, K. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation 2014, 129, 896–906.
56. Hackmann, A.E.; Rubin, B.G.; Sanchez, L.A.; Geraghty, P.A.; Thompson, R.W.; Curci, J.A. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J. Vasc. Surg. 2008, 48, 519–526.
57. Nagasawa, A.; Yoshimura, K.; Suzuki, R.; Mikamo, A.; Yamashita, O.; Ikeda, Y.; Tsuchida, M.; Hamano, K. Important role of the angiotensin II pathway in producing matrix metalloproteinase-9 in human thoracic aortic aneurysms. J. Surg. Res. 2013, 183, 472–477.
58. Yamashita, O.; Yoshimura, K.; Nagasawa, A.; Ueda, K.; Morikage, N.; Ikeda, Y.; Hamano, K. Periostin links mechanical strain to inflammation in abdominal aortic aneurysm. PLoS ONE 2013, 8, e79753.
59. Onoda, M.; Yoshimura, K.; Aoki, H.; Ikeda, Y.; Morikage, N.; Furutani, A.; Matsuzaki, M.; Hamano, K. Lysyl oxidase resolves inflammation by reducing monocyte chemoattractant protein-1 in abdominal aortic aneurysm. Atherosclerosis 2010, 208, 366–369.